We know you’re concerned about seizures

We also know seizures aren’t your only concern.

Information on Lennox-Gastaut Syndrome

Fact Sheet on Lennox-Gastaut Syndrome

"When Your Child Has Lennox-Gastaut Syndrome"

The Jackie and Alyssa Disante Story

“She is a little miracle to us every day.” That’s how Jackie Disante describes her daughter, Alyssa, an 11-year-old with Lennox-Gastaut syndrome (LGS). A severe form of epilepsy that accounts for up to 10 percent of all childhood cases, LGS can, in some cases, be fatal.

Alyssa experienced her first seizure a day before her second birthday. “I was called at work and told that there was an emergency and that I needed to go home,” Jackie remembers. “That drive home was the worst half-hour of my life.”

Alyssa was taken to a hospital emergency room, where she was diagnosed as having a seizure disorder. Within a few weeks, she was experiencing about 80 to 100 seizures a day. “She either seized or she slept. We held her 24 hours a day.”

Alyssa suffered from drop seizures - severe seizures characterized by a brief loss of muscle tone and unconsciousness that causes the affected person to fall. “The drop seizures were the worst part; they were violent and came on without any warning,” says Jackie. Like many children with Lennox-Gastaut, Alyssa was required to wear a helmet, along with elbow and knee pads, to protect herself from serious injury.

Because Alyssa needed full-time care, Jackie was forced to quit her job to be with her child around the clock. While at home, her free time was spent researching her daughter’s condition.

“At the time, I didn’t realize that ‘seizure disorder’ meant ‘epilepsy,’” Jackie recalls. And Alyssa’s doctors still hadn’t confirmed her diagnosis. Frustrated, but driven, Jackie searched for whatever information she could find and sought a second opinion. “My first question to the neurologist in the initial meeting was, ‘Do you think Alyssa has Lennox-Gastaut?’ to which he immediately responded, ‘yes, absolutely.’”

At this point, Alyssa was taking 5 antiepileptic drugs (AEDs) a day, but those medications couldn’t control her seizures. The physician gradually weaned Alyssa off these medications, and tried a combination of 2 new ones instead. “With the new medications, her seizures lessened, but they still weren’t controlled,” Jackie says.

When Alyssa was 6, her physician enrolled her in a new research study investigating the use of TOPAMAX - a new-generation AED-to treat Lennox-Gastaut syndrome in children. “When Alyssa began taking TOPAMAX, we saw immediate improvement,” Jackie remembers. “Her seizures lessened, and now they usually only occur when she’s sick, or sometimes when she’s sleeping.”

Four years later, Alyssa’s seizures are still under control with a combination of TOPAMAX and a traditional AED, and life has taken on new meaning. “For so long, we never saw our daughter smile, and it’s hard to explain how much that hurt,” Jackie says. “Now, she is amazing-so full of personality and able to enjoy her life.”

Individual results may vary. TOPAMAX is approved as add-on therapy for adults and children ages 2 to 16 with seizures associated with Lennox-Gastaut syndrome, partial-onset seizures or primary, generalized tonic-clonic seizures.


When used in combination with traditional antiepileptic drugs in clinical trials, some side effects occurred, but were generally temporary. The most common side effects associated with TOPAMAX in children included excessive drowsiness, loss of appetite, fatigue, nervousness, poor concentration, weight loss, aggressive reaction with memory difficulty. Safety and effectiveness in children younger than 2 have not been established. In adults, the most common types of side effects were sleepiness, dizziness, poor coordination, speech difficulty, slowed thinking, blurred or double vision, memory difficulties and changes in sensation.

About TOPAMAX

TOPAMAX is approved as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

TOPAMAX is approved as add-on therapy for patients 2 years of age and older with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.

Important Safety Information

Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.

Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.

More common side effects in adults are nervousness, coordination problems, fatigue, speech problems, slowed thinking, memory difficulty, tingling in arms and legs, and double vision; and in children, fatigue, loss of appetite, nervousness, memory difficulty, aggressive behavior, and weight loss.

As monotherapy, the most common side effects of TOPAMAX (in the 400 mg/day group and at a rate higher than the 50 mg/day group) in adults were tingling in arms and legs, weight decrease, sleepiness, loss of appetite, dizziness, and difficulty with memory; and in children, weight decrease, upper respiratory tract infection, tingling in arms and legs, loss of appetite, diarrhea, and mood problems.

In combination with other antiepileptic drugs (AEDs), the most common side effects of TOPAMAX in adults (200 to 400 mg/day) were sleepiness, dizziness, nervousness, loss of muscle coordination, fatigue, speech disorders and related problems, psychomotor slowing, abnormal vision, difficulty with memory, tingling in arms and legs, and double vision; and in children (5 to 9 mg/kg/day), fatigue, sleepiness, loss of appetite, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease.

Tell your doctor about other medications you take.

Please see full U.S. Prescribing Information.

© Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1999-2009. All rights reserved.

Your use of the information on this site is subject to the terms of our Legal Statement. Please see our Privacy Policy.

This site is published by Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which is solely responsible for its contents.

Capitalized product names are trademarks of Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

This information is intended for use by our customers, patients and healthcare professionals in the United States only. Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States.

This site was last modified on: Jul 26 2007 at 13:45:29 EDT